BioSpace News Archive

FSD Pharma Inc. today announces that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Volastra Therapeutics , an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry.

Agilent Technologies Inc. (NYSE: A) today announced Christoph Herwig has been selected to receive a prestigious Agilent Thought Leader Award.

Antech Diagnostics is advancing its leadership in canine cancer diagnostics to support early detection and personalized care pathways for dogs with cancer.

Virtis Health announced the unveiling of ambulatory infusion centers in Columbus and Cleveland, Ohio.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that it signed an amendment to its agreement with its 3CL protease biology theranostics partner NLC Pharma, Ltd.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company, announced a 1-for-30 reverse split of its Common Stock, par value $0.001, effective at 5:00 pm Eastern time.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the publication of preclinical data showing the effect of sodium phenylbutyrate (PB) and taurursodiol (TURSO, also known as ursodoxicoltaurine) on the transcriptomic and metabolomic profiles of primary skin fibroblasts from adults with sporadic amyotrophic lateral sclerosis (ALS) and adults without ALS.

CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) annual Congress on September 10, 2022 in Paris, France.

Ontogen Medtech, a Chicago-based medical device design and development services company, has been awarded a $258,793 Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institute of Health (NIH) to develop an innovative catheter device to improve the treatment of pulmonary embolism.